Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer | NCT07733908

NCT07733908

Overview

NCT ID: NCT07733908
Lead Sponsor: Aditya BagrodiaOTHER
Official Title: Efficacy of Posluma PET Scan in Evaulation and Monitoring of Patients Undergoing Focal Therapy for Prostate Cancer
Brief Summary: To determine the effectiveness of Posluma PET Scan for monitoring prostate cancer patients after targeted treatment, including how accurately it can detect any remaining or returning cancer after about 12 months post-treatment.
Conditions: Prostate Cancer
Interventions: Posluma PET

Status and Timeline

Status: Not yet recruiting
Last Update Posted: Jul 29, 2026Actual
Start Date: Aug 2026Estimated
Primary Completion Date: Jul 2030Estimated
Completion Date

Participation Criteria

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: Male
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Diagnosis: Histologically confirmed PCa.

Risk Profile: Intermediate-risk , organ-confined PCa

Eligibility for Focal Therapy: Determined to be an appropriate candidate for focal therapy based on clinical evaluation.

Age: 18 years or older.

Life Expectancy: Expected survival of at least 10 years.

Informed Consent: Ability to understand and willingness to sign the informed consent form.

Exclusion Criteria:

Previous Treatment: Prior treatment for PCa, including radiation therapy, chemotherapy, focal therapy, or androgen deprivation therapy.

Severe Comorbid Conditions: Presence of severe comorbid conditions that may interfere with study participation, such as uncontrolled cardiovascular, renal, hepatic, or metabolic diseases.

Contraindications to Imaging: Known hypersensitivity to components of the Posluma PSMA radiotracer, or inability to undergo PET or MRI imaging due to medical or anatomical constraints (e.g., severe claustrophobia, metallic implants incompatible with MRI).

Study Plan

Study Type: Interventional
Phase: Phase 2
Enrollment: 22Estimated
Primary Purpose: Supportive Care
Allocation: Non-Randomized
Interventional Model: Single Group Assignment
Masking: None (Open Label)

Contacts and Locations

Central Contacts: Translational Research TeamContact
CancerCTO@health.ucsd.edu(858) 822-5354

Similar Studies

Participant Group/Arms

Posluma PETExperimental

Participants will undergo Posluma PSMA PET scans at two time points: preoperatively to evaluate the extent of disease prior to focal therapy and postoperatively for monitoring treatment success and detecting potential recurrence. The Posluma PET imaging will be conducted on a PET/CT scanner with optimized protocols for PCa lesion detection. PET scan data will be analyzed in comparison with MRI and biopsy results. All imaging will be performed at UCSD, ensuring consistent imaging quality and scanner calibration across all patients.

Diagnostic Test: Posluma PET